` RLF (Relief Therapeutics Holding SA) vs Swiss Market Index Comparison - Alpha Spread

RLF
vs
S
Swiss Market Index

Over the past 12 months, RLF has significantly outperformed Swiss Market Index, delivering a return of +134% compared to the Swiss Market Index's 0% drop.

Stocks Performance
RLF vs Swiss Market Index

Loading
RLF
Swiss Market Index
Add Stock
www.alphaspread.com

Performance Gap
RLF vs Swiss Market Index

Loading
RLF
Swiss Market Index
Difference
www.alphaspread.com

Performance By Year
RLF vs Swiss Market Index

Loading
RLF
Swiss Market Index
Add Stock

Competitors Performance
Relief Therapeutics Holding SA vs Peers

Swiss Market Index
RLF
ABBV
AMGN
GILD
VRTX
Add Stock

Relief Therapeutics Holding SA
Glance View

Market Cap
36.7m CHF
Industry
Biotechnology

RELIEF THERAPEUTICS Holding AG is a clinical stage biotechnology company. The company is headquartered in Geneve, Geneve and currently employs 55 full-time employees. The company went IPO on 2011-09-19. The Company’s objective is to provide patients with therapeutic relief in serious diseases with high unmet medical need, as well as to focus on developing treatments for respiratory diseases. The company specializes in clinical-stage projects based on molecules of natural origin (peptides and proteins with a history of clinical use and either initial human activity with efficacy data or a strong scientific rationale. Its lead compound is RLF-100 (aviptadil), a synthetic human vasoactive intestinal peptide (VIP) with a multifaceted mode of action in respiratory indications. RLF-100 is being investigated in two placebo-controlled U.S. phase 2b/3 clinical trials in respiratory deficiency due to COVID-19. Its RLF-100 is also used for pulmonary sarcoidosis. The firm is also involved in the clinical development of RLF-100 that is in planning stage for other indications in acute and chronic lung diseases.

RLF Intrinsic Value
21.98 CHF
Undervaluation 88%
Intrinsic Value
Price
Back to Top